Nanoparticulate drug delivery systems for cancer chemotherapy

被引:124
作者
Saha, Ranendra N. [1 ]
Vasanthakumar, Sekar [1 ]
Bende, Girish [1 ]
Snehalatha, Movva [1 ]
机构
[1] BITS, Formulat Dev & Pharmacokinet Lab, Pharm Grp, FD 3, Pilani 333031, Rajasthan, India
关键词
Polymeric/lipid nanoparticles; opsonization; intracellular trafficking; cytotoxicity; brain targeting; ETOPOSIDE-LOADED PLGA; BIODEGRADABLE NANOPARTICLES; CHITOSAN NANOPARTICLES; TARGETED DELIVERY; ANTICANCER DRUGS; BRAIN DELIVERY; SOLID TUMOR; RELEASE; DESIGN; PHARMACOKINETICS;
D O I
10.3109/09687688.2010.510804
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nanoparticles (NPs) are, in general, colloidal particles, less than 1000 nm, that can be used for better drug delivery and prepared either by encapsulating the drug within a vesicle and or by dispersing the drug molecules within a matrix. Nanoparticulate drug delivery systems have been extensively studied in recent years for spatial and temporal delivery, especially in tumour and brain targeting. NPs have great promise for better drug delivery as found in both pharmaceutical and clinical research. As a drug carrier, NPs have significant advantages like better bioavailability, systemic stability, high drug loading, long blood circulation time and selective distribution in the organs/tissues with longer half life. The selective targeting of NPs can be achieved by the enhanced permeability and retention effect (EPR-effect), attaching specific ligands, or by making selective distribution due to change of the physiological conditions of specific systems like nature, pH, temperature, etc. It has been observed that drug-loaded NPs can have selective distribution to organs/tissues using different types of and proportions of polymers. The current aim of researchers is to prepare NPs that are long-lived with and that demonstrate the appropriate selective distribution for better therapy and thus improved clinical outcomes. Nanoparticulate drug delivery systems have the potential to deliver a drug to the target site with specificity and to maintain the desired concentration at the site for the intended time without untoward effects. In this review article, the methods for the preparation of NPs, their characterization, biodistribution, and pharmacokinetic characteristics are discussed.
引用
收藏
页码:215 / 231
页数:17
相关论文
共 88 条
[71]  
Snehalatha M, 2008, DRUG DELIV, V15, P277, DOI [10.1080/10717540802006500, 10.1080/10717540802006500 ]
[72]  
STEPHANIE EAG, 2007, J CONTROL RELEASE, V121, P10
[73]  
Stewart BW, 2003, WORLD CANC REPORT IN
[74]   SURFACE MODIFICATION OF POLY(LACTIDE-CO-GLYCOLIDE) NANOSPHERES BY BIODEGRADABLE POLY(LACTIDE)-POLY(ETHYLENE GLYCOL) COPOLYMERS [J].
STOLNIK, S ;
DUNN, SE ;
GARNETT, MC ;
DAVIES, MC ;
COOMBES, AGA ;
TAYLOR, DC ;
IRVING, MP ;
PURKISS, SC ;
TADROS, TF ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (12) :1800-1808
[75]   Chitosan and its derivatives as intestinal absorption enhancers [J].
Thanou, M ;
Verhoef, JC ;
Junginger, HE .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 :S91-S101
[76]   Targeted pharmaceutical nanocarriers for cancer therapy and Imaging [J].
Torchilin, Vladimir P. .
AAPS JOURNAL, 2007, 9 (02) :E128-E147
[77]   Targeting the central nervous system:: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123 [J].
Tosi, G. ;
Costantino, L. ;
Rivasi, F. ;
Ruozi, B. ;
Leo, E. ;
Vergoni, A. V. ;
Tacchi, R. ;
Bertolini, A. ;
Vandelli, M. A. ;
Forni, F. .
JOURNAL OF CONTROLLED RELEASE, 2007, 122 (01) :1-9
[78]   Influence of phase transformation on indomethacin release from microemulsions [J].
Trotta, M .
JOURNAL OF CONTROLLED RELEASE, 1999, 60 (2-3) :399-405
[79]   Freeze drying - principles and practice for successful scale-up to manufacturing [J].
Tsinontides, SC ;
Rajniak, P ;
Pham, D ;
Hunke, WA ;
Placek, J ;
Reynolds, SD .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 280 (1-2) :1-16
[80]   How to concentrate nanoparticles and avoid aggregation? [J].
Vauthier, C. ;
Cabane, B. ;
Labarre, D. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 69 (02) :466-475